Boston Trust Walden Corp Lowers Stock Position in Stryker Corporation $SYK

Boston Trust Walden Corp trimmed its holdings in Stryker Corporation (NYSE:SYK) by 0.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 280,004 shares of the medical technology company’s stock after selling 1,797 shares during the quarter. Boston Trust Walden Corp’s holdings in Stryker were worth $92,007,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Godfrey Financial Associates Inc. purchased a new position in Stryker during the 4th quarter worth $26,000. Sankala Group LLC purchased a new stake in shares of Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker during the third quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker during the fourth quarter worth about $27,000. Finally, DJE Kapital AG purchased a new position in shares of Stryker during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Barclays dropped their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. Canaccord Genuity Group dropped their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. William Blair restated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Finally, Robert W. Baird set a $385.00 price target on Stryker in a report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $395.33.

Stryker Stock Performance

NYSE SYK opened at $326.41 on Friday. The stock has a market capitalization of $125.13 billion, a price-to-earnings ratio of 37.78, a PEG ratio of 2.01 and a beta of 0.77. The business’s 50 day moving average is $309.86 and its two-hundred day moving average is $338.96. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Insider Transactions at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This trade represents a 28.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last ninety days. 4.60% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.